Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study
Open Access
- 1 August 2000
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 110 (2) , 300-307
- https://doi.org/10.1046/j.1365-2141.2000.02149.x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSFBone Marrow Transplantation, 1999
- Mucositis: Its Occurrence, Consequences, and Treatment in the Oncology SettingThe Oncologist, 1998
- Amifostine stimulates formation of multipotent and erythroid bone marrow progenitorsLeukemia, 1998
- EP-2 What the non-surgeons have to know about surgery?European Journal Of Cancer, 1996
- Amifostine (Ethyol®): Dosing, administration and patient management guidelinesEuropean Journal Of Cancer, 1996
- Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.Journal of Clinical Oncology, 1996
- Amifostine (WR-2721) Protects Normal Haematopoietic Stem Cells Against Cyclophosphamide Derivatives' Toxicity Without Compromising Their Antileukaemic EffectsEuropean Journal Of Cancer, 1995
- Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purgingBlood, 1995
- Hypocalcemia and Inhibition of Parathyroid Hormone Secretion after Administration of WR-2721 (a Radioprotective and Chemoprotective Agent)New England Journal of Medicine, 1983
- Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor ResponseScience, 1977